Tyme Technologies Stock Forecast, Price & News

Tyme Technologies (NASDAQ:TYME) Frequently Asked Questions

How has Tyme Technologies' stock price been impacted by COVID-19?

Tyme Technologies' stock was trading at $1.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TYME stock has decreased by 24.8% and is now trading at $0.79.
View which stocks have been most impacted by COVID-19.

When is Tyme Technologies' next earnings date?

Tyme Technologies is scheduled to release its next quarterly earnings announcement on Thursday, February 3rd 2022.
View our earnings forecast for Tyme Technologies.

How were Tyme Technologies' earnings last quarter?

Tyme Technologies, Inc. (NASDAQ:TYME) released its earnings results on Monday, November, 8th. The company reported ($0.03) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.06) by $0.03.
View Tyme Technologies' earnings history.

Who are Tyme Technologies' key executives?

Tyme Technologies' management team includes the following people:

• Steve Hoffman, Chairman & Chief Science Officer (LinkedIn Profile)
• Richard Anthony Cunningham, Chief Executive Officer & Director
• Frank L. Porfido, Chief Financial Officer
• Jan M. van Tornout, Chief Medical Officer
• Jonathan M. Eckard, Chief Business Officer

Who are some of Tyme Technologies' key competitors?

Some companies that are related to Tyme Technologies include ORIC Pharmaceuticals (ORIC), Immuneering (IMRX), ANI Pharmaceuticals (ANIP), PyroGenesis Canada (PYR), G1 Therapeutics (GTHX), Chimerix (CMRX), Pharming Group (PHAR), Basilea Pharmaceutica (BPMUF), Intercept Pharmaceuticals (ICPT), Summit Therapeutics (SMMT), Avadel Pharmaceuticals (AVDL), Ocular Therapeutix (OCUL), Nkarta (NKTX), Deciphera Pharmaceuticals (DCPH) and Gracell Biotechnologies (GRCL).
View all of TYME's competitors.

What other stocks do shareholders of Tyme Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tyme Technologies investors own include Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Vaxart (VXRT), Allena Pharmaceuticals (ALNA), OpGen (OPGN), Selecta Biosciences (SELB), MEI Pharma (MEIP), Pfizer (PFE) and SCYNEXIS (SCYX).

What is Tyme Technologies' stock symbol?

Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."

Who are Tyme Technologies' major shareholders?

Tyme Technologies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.21%), Healthcare Value Capital LLC (1.16%), Millennium Management LLC (0.82%), Geode Capital Management LLC (0.44%), Renaissance Technologies LLC (0.32%) and Morgan Stanley (0.09%). Company insiders that own Tyme Technologies stock include Barbara Galaini, David Carberry, Diana F Cantor, Douglas A Michels, James Biehl, Michael Demurjian, Steve Hoffman, Tornout Jan M Van and Tornout Jan M Van.
View institutional ownership trends for Tyme Technologies.

Which major investors are selling Tyme Technologies stock?

TYME stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Morgan Stanley, Geode Capital Management LLC, Barclays PLC, Goldman Sachs Group Inc., and Bank of New York Mellon Corp. Company insiders that have sold Tyme Technologies company stock in the last year include Diana F Cantor, Michael Demurjian, and Steve Hoffman.
View insider buying and selling activity for Tyme Technologies or view top insider-selling stocks.

Which major investors are buying Tyme Technologies stock?

TYME stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Healthcare Value Capital LLC, BlackRock Inc., Citadel Advisors LLC, HighTower Advisors LLC, Wolverine Trading LLC, and HAP Trading LLC. Company insiders that have bought Tyme Technologies stock in the last two years include Barbara Galaini, David Carberry, Douglas A Michels, James Biehl, Michael Demurjian, and Tornout Jan M Van.
View insider buying and selling activity for Tyme Technologies or or view top insider-buying stocks.

How do I buy shares of Tyme Technologies?

Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tyme Technologies' stock price today?

One share of TYME stock can currently be purchased for approximately $0.79.

How much money does Tyme Technologies make?

Tyme Technologies has a market capitalization of $136.04 million. The company earns $-28.98 million in net income (profit) each year or ($0.16) on an earnings per share basis.

How many employees does Tyme Technologies have?

Tyme Technologies employs 18 workers across the globe.

What is Tyme Technologies' official website?

The official website for Tyme Technologies is www.tymeinc.com.

Where are Tyme Technologies' headquarters?

Tyme Technologies is headquartered at 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004.

How can I contact Tyme Technologies?

Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at (212) 461-2315 or via email at [email protected].